PRIMARY CHEMOTHERAPY WITH AN EXTENDED SCHEDULE OF TEMOZOLOMIDE (1 WeEK ON / 1 WEEK OFF) FOR LOW GRADE OLIGODENDROGLIAL TUMORS AT RELAPSE OR PROGRESSION AFTER SURGERY: PHASE II TRIAL.
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Temozolomide (Primary)
- Indications Astrocytoma; Oligodendroglioma
- Focus Therapeutic Use
- Acronyms TEMODAL
- 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 02 Jun 2017 Status changed from recruiting to completed according to results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 21 Jul 2011 New trial record